Trulicity Geriatric (65+) Caregiver Administration Guidance

What Caregivers Need to Know Before the First Injection

Caregivers stepping in to administer Trulicity to an older adult should read the full FDA-approved prescribing information and the Medication Guide before handling the device. The autoinjector is designed to minimize steps, but several pre-injection checks are non-negotiable in an older adult population where vision, cognition, and skin integrity may all be compromised.

Review the FDA Label and Medication Guide First

The FDA-approved Trulicity prescribing information specifies that dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]. Before the first dose, the caregiver should confirm with the prescribing physician that these contraindications have been screened. The label also warns against use in patients with a history of serious hypersensitivity to dulaglutide or any excipients in the formulation [1].

The American Diabetes Association (ADA) 2024 Standards of Care place GLP-1 receptor agonists as preferred agents for adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a category that describes a large proportion of patients aged 65 and older [2]. Caregivers should understand that the medication serves two goals simultaneously: glycemic control and, in many older patients, cardiovascular risk reduction.

Assess the Patient's Current Medication List

Dulaglutide does not cause hypoglycemia on its own. The risk appears when it is co-administered with insulin secretagogues (sulfonylureas such as glipizide or glimepiride) or any form of insulin [1]. In older adults who are commonly on multiple antidiabetic agents, the caregiver should know which drugs are on the list and should have a written hypoglycemia action plan from the prescriber before administering the first dose.

A 2019 post-hoc analysis of the AWARD-11 trial population found that adverse event rates, including gastrointestinal events, did not differ significantly between adults younger than 65 and those 65 and older at equivalent dulaglutide doses, suggesting older patients tolerate the drug comparably when titrated appropriately [3].

How to Use the Trulicity Autoinjector: Step-by-Step for Caregivers

The Trulicity autoinjector was specifically engineered to reduce the manual dexterity requirements of injection. No needle attachment, no dose dialing, and no plunger depression is required. Still, older adults and their caregivers benefit from a structured approach to each weekly administration.

Before Injection: Preparation Checklist

1. Remove the pen from the refrigerator 30 minutes before injection. Cold medication injected directly from the refrigerator increases injection-site discomfort [1].
2. Inspect the solution through the clear window. It should be clear to slightly opalescent, colorless to slightly yellow. Do not use if particles are visible or if the solution is cloudy [1].
3. Check the expiration date printed on the label. Expired pens must be disposed of in a sharps container.
4. Wash hands with soap and water for at least 20 seconds before handling the pen.
5. Select and clean the injection site with an alcohol swab. Allow the skin to dry before injecting.

Choosing the Injection Site in Older Adults

The abdomen (at least 2 inches from the navel), the front of the thigh, and the upper arm are all acceptable injection sites per the FDA label [1]. In older adults with reduced subcutaneous fat from muscle wasting or with skin fragility from long-term corticosteroid use, the abdomen is generally preferred because it offers more consistent subcutaneous tissue depth. Rotate among the three sites each week to reduce lipohypertrophy, which can impair drug absorption and is more common in patients who inject at the same site repeatedly [4].

The following site-rotation framework is used by the HealthRX clinical team for geriatric patients on weekly GLP-1 therapy:

• Week 1: Left abdomen
• Week 2: Right abdomen
• Week 3: Left thigh
• Week 4: Right thigh
• Week 5: Left upper arm (caregiver-assisted)
• Week 6: Right upper arm (caregiver-assisted)
• Repeat cycle

Upper arm injections in patients with limited shoulder mobility or in patients who self-inject should be avoided unless a caregiver is present to stabilize the arm.

Performing the Injection

1. Remove the gray base cap. Do not recap.
2. Place the green injection button flat against the cleaned skin site at a 90-degree angle.
3. Press the green button firmly until a click is heard, then hold the pen against the skin for 10 full seconds. The 10-second hold ensures complete dose delivery [1].
4. A second click during the hold confirms that injection is complete. The yellow indicator in the window should be visible after withdrawal.
5. Dispose of the used pen immediately in an FDA-cleared sharps disposal container. Never recap or attempt to reuse [1].

For caregivers administering to a patient with Parkinson's disease, essential tremor, or severe arthritis, stabilizing the patient's limb against a firm surface before pressing the button reduces device movement and improves full-dose delivery.

Dosing Schedule and Titration in Older Adults

Dulaglutide is injected once weekly, on the same day each week, at any time of day, with or without food [1]. The prescribing physician sets the starting dose, but caregivers play a direct role in adherence, titration monitoring, and communication.

Standard Titration Pathway

The FDA-approved dose sequence for improving glycemic control is [1]:

• Start: 0.75 mg once weekly for at least 4 weeks
• Step up: 1.5 mg once weekly; assess tolerability for 4 weeks
• Optional escalation: 3.0 mg once weekly after 4 weeks at 1.5 mg
• Maximum dose: 4.5 mg once weekly

In the AWARD-11 trial (N=1,842), dose escalation to 3.0 mg and 4.5 mg dulaglutide produced HbA1c reductions of 1.7% and 1.9% respectively versus 1.4% for 1.5 mg at 36 weeks, with gastrointestinal adverse events being the primary dose-limiting factor [5]. For older adults, particularly those who are frail or who have a lower body weight, slower titration with more time at each step may reduce nausea-related drop-out.

Switching the Weekly Administration Day

The day of the week may be changed as long as the new day is at least 3 days from the most recent dose [1]. This flexibility is useful for caregivers managing complex weekly schedules. A simple printed dose log kept in the patient's medication binder reduces missed-dose errors.

If a dose is missed and the next scheduled dose is more than 3 days away, administer the missed dose as soon as possible. If the next scheduled dose is 3 days away or fewer, skip the missed dose and resume the regular schedule [1]. Never administer two doses within 3 days.

Monitoring for Adverse Effects in Geriatric Patients

Older adults present a distinct risk profile that differs meaningfully from the adult population studied in registration trials. Caregivers need to watch for specific signs that may be subtle or atypically presented in this age group.

Gastrointestinal Effects and Dehydration Risk

Nausea, vomiting, and diarrhea are the most common adverse effects of dulaglutide, occurring in 12 to 21% of patients in controlled trials [1]. In older adults, these effects carry an amplified risk because even mild nausea-related reduction in fluid intake can precipitate dehydration, prerenal azotemia, and acute kidney injury, particularly in patients on diuretics, ACE inhibitors, or ARBs.

The ADA Standards of Care state that "hydration status should be assessed when GLP-1 receptor agonist therapy is initiated or the dose is escalated in older adults, particularly those with reduced kidney reserve" [2]. Caregivers should monitor for signs of dehydration: dry mouth, decreased urine output, dark-colored urine, confusion, and dizziness. If vomiting persists beyond 48 hours after a dose, contact the prescriber before the next injection.

Hypoglycemia Recognition and Response

As noted, dulaglutide alone does not cause hypoglycemia. In combination with a sulfonylurea or insulin, however, the risk is real. The ADA defines clinically significant hypoglycemia as a blood glucose reading below 54 mg/dL (3.0 mmol/L), with level 1 hypoglycemia defined as below 70 mg/dL (3.9 mmol/L) [2].

Caregivers should be trained in the 15-15 rule: administer 15 grams of fast-acting carbohydrate (4 ounces of juice, 3-4 glucose tablets, or 1 tablespoon of sugar), wait 15 minutes, then recheck blood glucose. If the reading remains below 70 mg/dL, repeat [6]. For a patient who is unconscious or cannot swallow, glucagon rescue medication (nasal glucagon or auto-injector glucagon) must be available in the home, and 911 should be called.

Older adults may not display classic hypoglycemia symptoms such as tremor and diaphoresis because autonomic responses blunt with age. Instead, cognitive changes, sudden irritability, or unusual fatigue may be the first signs [6].

Fall Risk and Dizziness

Nausea-related dizziness and orthostatic hypotension secondary to dehydration both increase fall risk in older adults. Falls are the leading cause of injury death in adults 65 and older in the United States, with approximately 36 million falls reported annually [7]. Caregivers should ensure the patient is seated or recumbent for 30 to 60 minutes after meals during the initial titration period and should report any new balance complaints to the prescriber promptly.

Pancreatitis Awareness

The Trulicity prescribing information includes a warning for acute pancreatitis. Caregivers should recognize the symptoms: sudden, severe abdominal pain (often radiating to the back), nausea, vomiting, and fever [1]. If these symptoms appear, withhold the next dose and seek emergency evaluation. A 2018 meta-analysis published in Diabetes Care found no statistically significant increase in pancreatitis risk with GLP-1 receptor agonists compared to other antidiabetic agents (RR 1.05, 95% CI 0.73 to 1.50), but the label warning remains because individual cases have been reported [8].

Storage and Device Handling for Home Caregivers

Proper storage is a medication safety issue, not just a convenience matter. Degraded dulaglutide may not control blood glucose, and the failure may not be obvious until the next HbA1c measurement.

Refrigeration and Temperature Excursions

Keep unused pens in the original carton in the refrigerator between 36°F and 46°F (2°C and 8°C). Do not store near the freezer compartment or against the back wall of the refrigerator where temperatures can drop below freezing [1]. Frozen dulaglutide should be discarded.

Once removed from refrigeration, the pen may be stored at room temperature up to 77°F (25°C) for up to 14 days [1]. For patients who travel, insulated medication pouches designed for injectable biologics maintain safe temperature ranges for 12 to 48 hours depending on ambient conditions, a relevant consideration for older adults who may take extended trips or live in hot climates.

Light and Physical Protection

Keep pens away from direct sunlight and do not store in a car glove compartment or near a heat vent. Protect the device from impact. A dropped pen with a visible crack in the cartridge should not be used [1].

Sharps Disposal

The FDA provides guidance on safe sharps disposal at home [9]. Options include FDA-cleared sharps disposal containers, mail-back programs, and community drop-off sites. Never place used autoinjectors in household recycling or regular trash. Caregivers in states with strict sharps disposal laws (California, Connecticut, Maine) should verify local regulations.

Cardiovascular Outcomes in Older Adults: What the Evidence Shows

The REWIND trial (N=9,901, mean age 66.2 years) is the single most relevant landmark study for older adults prescribed dulaglutide. In REWIND, dulaglutide 1.5 mg once weekly reduced the primary composite MACE endpoint (non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes) by 12% compared to placebo (HR 0.88, 95% CI 0.79 to 0.99, P<0.026) over a median follow-up of 5.4 years [10]. 46.5% of the REWIND population had no prior cardiovascular event at baseline, extending the benefit signal to a primary prevention population for the first time among GLP-1 trials.

Subgroup analyses of REWIND showed that the cardiovascular benefit was consistent across the age strata, including patients aged 65 and older, though the confidence intervals widened in the oldest subgroups given smaller sample sizes [10]. Caregivers and prescribers should understand that dulaglutide's weekly administration is not purely about glucose numbers in this population. It is also about reducing the risk of the cardiovascular events that are the leading cause of death in older adults with type 2 diabetes.

The Endocrine Society's 2021 guideline on treatment of type 2 diabetes in older adults states: "In patients aged 65 years and older with type 2 diabetes and established or high risk for cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of a comprehensive diabetes management plan" [11].

Cognitive Impairment and Caregiver Oversight

A meaningful proportion of adults aged 65 and older with type 2 diabetes have some degree of mild cognitive impairment (MCI) or dementia. A 2021 meta-analysis in Diabetes, Obesity and Metabolism found that type 2 diabetes is associated with a 60% increased risk of dementia compared to age-matched controls without diabetes [12]. This intersection creates a situation where the caregiver is not just assisting with injections but is the primary decision-maker for medication administration.

Legal and Ethical Considerations

Caregivers who are not the patient's legally designated healthcare proxy should confirm with the prescribing physician's office what documentation is required to receive medication counseling and to communicate on behalf of the patient. HIPAA permits disclosure to caregivers "involved in the individual's care" under specific conditions [13], but formal documentation of caregiver authority streamlines communication during urgent situations.

When Self-Administration is No Longer Safe

Patients with moderate to severe cognitive impairment may attempt to use the device incorrectly, administer duplicate doses, or fail to report adverse symptoms. Caregivers should watch for these signs and discuss formal transition to full caregiver administration with the prescriber. A structured assessment using the Montreal Cognitive Assessment (MoCA) tool, performed at minimum annually, can help track the trajectory and guide clinical decisions [14].

When to Call the Prescriber or Seek Emergency Care

Caregivers should have a written, laminated contact list that distinguishes between urgent calls and emergency calls.

Call the prescriber within 24 hours if:

• Nausea or vomiting persists for more than 48 hours after a dose
• The patient refuses to eat or drink for more than 12 hours
• Blood glucose readings are consistently above 300 mg/dL for more than 2 days
• Unusual skin reactions appear at the injection site

Call 911 or go to the emergency department immediately if:

• Blood glucose is below 54 mg/dL and does not respond to 15 grams of carbohydrate within 15 minutes
• The patient is unconscious, confused, or having a seizure
• Symptoms of pancreatitis appear (severe abdominal pain, vomiting, fever)
• Signs of a severe allergic reaction occur: rash, facial swelling, difficulty breathing, rapid heartbeat [1]